CHICAGO, Aug. 17, 2017 -- Allscripts (NASDAQ:MDRX) has partnered with Elligo Health Research to assist clinicians to conduct clinical trial studies in their own clinics. Through the Allscripts / Elligo partnership, clinical trials managed by Clinical Research Organizations (CROs) will be available, bringing new treatments to patients across major therapeutic areas.
The combined offering enables physicians to directly participate as study investigators in selected CRO clinical trials, and delivers the physicians’ patients the benefit of more direct comprehensive care. Additionally, physicians will be able to generate research revenue and cover investigator fees associated with trial procedures.
The Allscripts eParticipateSM service will be available to all Allscripts clients using the EHR platforms – Allscripts Professional EHR™, Allscripts TouchWorks® EHR and Allscripts Sunrise™.
CROs continue to increase investments to support bringing new clinical therapies to market, with more than $17 billion in payments to study investigators. eParticipate expands the reach of clinical trials investments by enabling Allscripts research-capable sites to become study investigators through Elligo’s infrastructure and services. Allscripts physicians will have access to clinical trials across several therapeutic areas, including Gastroenterology, Neurology, Pain, Urology, Pulmonology, Oncology and Women’s Health, some of the key areas of focus for CROs.
“By bringing clinical trials directly to their patients, physicians can remain focused on the direct care of patients while offering them new therapies,” said Allscripts Senior Vice President and General Manager of Payer and Life Sciences Jay Bhattacharyya. “Physicians will be able to participate in the benefits of clinical research without investing in expensive infrastructure.”
“Through our partnership with Allscripts, health care providers can identify patients for potential clinical research opportunities directly through their EHR,” said President of Elligo Health Research, Chad Moore. “Not only will patients gain access to treatments they might not have had otherwise, they will also participate from the comfort of their own physician’s office.”
About Allscripts
Allscripts (NASDAQ:MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.
About Elligo Health Research
Elligo Health Research offers the only platform that brings clinical research to the clinic, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Elligo Goes Direct™ with an approach that uses electronic health records and other health data to identify real-world physicians and patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.
© 2017 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.
Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.
For more information contact: Allscripts Investors: Seth Frank 312-506-1213 [email protected] Allscripts Media: Concetta Rasiarmos 312-447-2466 [email protected] Elligo Media: Lea Studer 308-237-5567


Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Shell M&A Chief Exits After BP Takeover Proposal Rejected
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
Robinhood Expands Sports Event Contracts With Player Performance Wagers
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 



